REGENXBIO (RGNX) IPO Prices In-Line at $22

REGENXBIO Inc. (NASDAQ: RGNX) announced the pricing of its initial public offering of 6,300,000 shares of its common stock at a public offering price of $22.00 per share, inline with the expected pricing. The number of shares offered was raised from 5,555,555 shares. The shares are scheduled to begin trading on The NASDAQ Global Select Market today under the ticker symbol "RGNX."

In addition, REGENXBIO granted the underwriters a 30-day option to purchase up to an additional 945,000 shares of its common stock at the same price.

Morgan Stanley and BofA Merrill Lynch are acting as active joint book-running managers of the proposed offering. Piper Jaffray is acting as a passive book-running manager. Chardan Capital Markets is acting as a co-manager.

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. REGENXBIO's NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, including five internally developed candidates and 18 partnered candidates developed by REGENXBIO's licensees.

You May Also Be Interested In

• Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
• UK’s EG Group reportedly files for US IPO worth about $1 billion
• CopperTech Metals files for IPO on NYSE under ticker CUX